Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast 2025-2034

Community-acquired bacterial pneumonia (CABP) is caused by bacterial pathogens such as Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. It is associated with high morbidity and mortality, with around 3 to 4 million people affected by community-acquired pneumonia each year.

Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast Report Coverage

The “Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of community-acquired bacterial pneumonia (CABP). It projects the future incidence and prevalence rates of community-acquired bacterial pneumonia (CABP) across various populations. The study covers age, gender, and type as major determinants of the community-acquired bacterial pneumonia (CABP)-affected population. The report highlights patterns in the prevalence of community-acquired bacterial pneumonia (CABP) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of community-acquired bacterial pneumonia (CABP) in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Community-Acquired Bacterial Pneumonia (CABP) Disease Overview

Community-acquired bacterial pneumonia (CABP) is a bacterial lung infection that is acquired outside of hospitals or healthcare settings. It is transmitted through inhaling respiratory droplets containing bacteria or through contact with contaminated surfaces. Common symptoms include cough, shortness of breath, fever, chills, and fatigue, among others. It is primarily caused by bacteria like Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens.

Community-Acquired Bacterial Pneumonia (CABP): Treatment Overview

Treatment of community-acquired bacterial pneumonia depends on the severity of the infection, patient profile, and the specific bacterial cause. First-line antibiotics such as amoxicillin, macrolides (azithromycin and clarithromycin), and doxycycline are commonly prescribed for mild cases of community-acquired bacterial pneumonia. For severe or hospitalized cases, beta-lactam antibiotics along with a macrolide or fluoroquinolone are given to the patient. Supportive care includes oxygen therapy, antipyretics and analgesics, and hydration.

Epidemiology

The community-acquired bacterial pneumonia (CABP) epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for community-acquired bacterial pneumonia (CABP) by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for community-acquired bacterial pneumonia (CABP) and its trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Around 3 to 4 million people worldwide are affected by community-acquired pneumonia. As per the WHO Global Burden of Disease study, lower respiratory tract infections (LRTIs), including community-acquired pneumonia are responsible for nearly 429.2 million episodes of illness.
• A 2020 United States study reported that around 967.470 adults (aged 65 and above) are hospitalized every year due to community-acquired pneumonia, showing a 38% one-year mortality.
• In community-acquired pneumonia cases, men are significantly linked with hospitalization and death, with the male population 1.3 times more prone to death than the female population.
• According to a 2018 retrospective analysis, the rate of community-acquired pneumonia among adults aged 65 years and above in a Medicare insurance plan was estimated to be 846.7 per 100,000 person-years.

Country-wise Community-Acquired Bacterial Pneumonia (CABP) Epidemiology

The community-acquired bacterial pneumonia (CABP) epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of community-acquired bacterial pneumonia (CABP) varies between countries owing to differences in factors such as the size of the aging population, vaccination rates, public health initiatives, and prevalence of risk behaviors (smoking and alcohol use), among others. India accounts for 23% of the global burden of community-acquired pneumonia, with the annual incidence rate estimated to be between 5 and 11 per 1000 people.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of community-acquired bacterial pneumonia (CABP) based on several factors.
• Community-Acquired Bacterial Pneumonia (CABP) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of community-acquired bacterial pneumonia (CABP) are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of community-acquired bacterial pneumonia (CABP) epidemiology in the 8 major markets?
• What will be the total number of patients with community-acquired bacterial pneumonia (CABP) across the 8 major markets during the forecast period?
• What was the country-wise prevalence of community-acquired bacterial pneumonia (CABP) in the 8 major markets in the historical period?
• Which country will have the highest number of community-acquired bacterial pneumonia (CABP) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of community-acquired bacterial pneumonia (CABP) during the forecast period of 2025-2034?
• What are the currently available treatments for community-acquired bacterial pneumonia (CABP)?
• What are the disease risks, signs, symptoms, and unmet needs of community-acquired bacterial pneumonia (CABP)?

This product will be delivered within 3-5 business days.